
|Articles|March 1, 2004
No user fee needed for extina
Connetics Corp. has received notifications from the FDA that no user fee is required for the new drug application seeking marketing clearance for Extina (ketoconazole 2 percent) Foam. Previously, Connects announced positive results from its Phase III clinical trial with Extina versus Nizoral.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















